Supplementary Figure 1. The risk of bias assessments across included studies. (A)
Overall risk of bias, showing review author's judgment about each risk of bias domain are presented as percentages across included studies;(B) study-level risk of bias, Green, low risk; Yellow, unclear; Red, high risk. Using Cochrane's risk of bias assessment, studies were considered to be at high, low, or unclear risk of bias based on (1) adequacy of sequence generation (2) allocation concealment (3) blinding (4) method of addressing incomplete data (5) incomplete outcome data (6) selective reporting (7) other bias. 'diclofenac':ab, ti OR 'indomethacin':ab, ti OR 'aspirin':ab, ti OR 'ibuprofen':ab, ti OR 'naproxen':ab, ti OR 'ketorolac':ab, ti OR 'etodolac':ab, ti OR 'sulindac':ab, ti OR 'celecoxib':ab, ti OR 'rofecoxib':ab, ti OR 'valdecoxib':ab, ti 
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